Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells.

Yazdanifar M, Zhou R, Mukherjee P.

Curr Trends Immunol. 2016;17:95-115.

2.

Characterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2.

Vongchan P, Linhardt RJ.

World J Hepatol. 2017 Mar 8;9(7):368-384. doi: 10.4254/wjh.v9.i7.368.

3.

GPC-3 in hepatocellular carcinoma: current perspectives.

Wu Y, Liu H, Ding H.

J Hepatocell Carcinoma. 2016 Nov 8;3:63-67. eCollection 2016. Review.

4.

HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration in in vitro Models.

Andreozzi M, Quintavalle C, Benz D, Quagliata L, Matter M, Calabrese D, Tosti N, Ruiz C, Trapani F, Tornillo L, Fusco A, Heim MH, Ng CK, Pallante P, Terracciano LM, Piscuoglio S.

Neoplasia. 2016 Dec;18(12):724-731. doi: 10.1016/j.neo.2016.10.002. Epub 2016 Nov 14.

5.

Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA).

Quagliata L, Schlageter M, Quintavalle C, Tornillo L, Terracciano LM.

Microarrays (Basel). 2014 Apr 15;3(2):91-102. doi: 10.3390/microarrays3020091. Review.

6.

Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.

Li W, Guo L, Rathi P, Marinova E, Gao X, Wu MF, Liu H, Dotti G, Gottschalk S, Metelitsa LS, Heczey A.

Hum Gene Ther. 2017 May;28(5):437-448. doi: 10.1089/hum.2016.025. Epub 2016 Aug 16.

PMID:
27530312
7.

Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma.

Ofuji K, Saito K, Yoshikawa T, Nakatsura T.

J Hepatocell Carcinoma. 2014 May 21;1:35-42. doi: 10.2147/JHC.S48517. eCollection 2014. Review.

8.

Latest developments in precancerous lesions of hepatocellular carcinoma.

Niu ZS, Niu XJ, Wang WH, Zhao J.

World J Gastroenterol. 2016 Mar 28;22(12):3305-14. doi: 10.3748/wjg.v22.i12.3305. Review.

9.

Clinical correlation of calpain-1 and glypican-3 expression with gallbladder carcinoma.

Luo W, Ren Z, Gao S, Jin H, Zhang G, Zhou L, Zheng S.

Oncol Lett. 2016 Feb;11(2):1345-1352. Epub 2016 Jan 7.

10.

Immunohistochemical expression of glypican 3 in endometrial carcinoma and correlation with prognostic parameters.

Hakim SA, Raboh NM.

Int J Clin Exp Pathol. 2015 Oct 1;8(10):13225-32. eCollection 2015.

11.

Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma.

Li K, Pan X, Bi Y, Xu W, Chen C, Gao H, Shi B, Jiang H, Yang S, Jiang L, Li Z.

Oncotarget. 2016 Jan 19;7(3):2496-507. doi: 10.18632/oncotarget.6595.

12.

Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel.

Hanaoka H, Nakajima T, Sato K, Watanabe R, Phung Y, Gao W, Harada T, Kim I, Paik CH, Choyke PL, Ho M, Kobayashi H.

Nanomedicine (Lond). 2015;10(7):1139-47. doi: 10.2217/nnm.14.194.

13.

Expression of Glypican 3 in low and high grade urothelial carcinomas.

Aydin O, Yildiz L, Baris S, Dundar C, Karagoz F.

Diagn Pathol. 2015 Apr 21;10:34. doi: 10.1186/s13000-015-0266-4.

14.

Bioinformatic and immunological analysis reveals lack of support for measles virus related mimicry in Crohn's disease.

Polymeros D, Tsiamoulos ZP, Koutsoumpas AL, Smyk DS, Mytilinaiou MG, Triantafyllou K, Bogdanos DP, Ladas SD.

BMC Med. 2014 Aug 28;12:139. doi: 10.1186/s12916-014-0139-9.

15.

Dysplastic nodules with glypican-3 positive immunostaining: a risk for early hepatocellular carcinoma.

Gong L, Wei LX, Ren P, Zhang WD, Liu XY, Han XJ, Yao L, Zhu SJ, Lan M, Li YH, Zhang W.

PLoS One. 2014 Jan 31;9(1):e87120. doi: 10.1371/journal.pone.0087120. eCollection 2014.

16.

Insidious changes in stromal matrix fuel cancer progression.

Miles FL, Sikes RA.

Mol Cancer Res. 2014 Mar;12(3):297-312. doi: 10.1158/1541-7786.MCR-13-0535. Epub 2014 Jan 22. Review.

17.

Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients.

Li B, Liu H, Shang HW, Li P, Li N, Ding HG.

Afr Health Sci. 2013 Sep;13(3):703-9. doi: 10.4314/ahs.v13i3.26.

18.

Glypican-3 antibodies: a new therapeutic target for liver cancer.

Feng M, Ho M.

FEBS Lett. 2014 Jan 21;588(2):377-82. doi: 10.1016/j.febslet.2013.10.002. Epub 2013 Oct 15. Review.

19.

PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells.

Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, Burga LN, Xie J, Jurczak MJ, DePinho RA, Clish CB, Jacks T, Kibbey RG, Wulf GM, Di Vizio D, Mills GB, Cantley LC, Vander Heiden MG.

Cell. 2013 Oct 10;155(2):397-409. doi: 10.1016/j.cell.2013.09.025.

20.

Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma.

Yao S, Zhang J, Chen H, Sheng Y, Zhang X, Liu Z, Zhang C.

J Histochem Cytochem. 2013 Sep;61(9):639-48. doi: 10.1369/0022155413492771. Epub 2013 May 16.

Supplemental Content

Support Center